JP2020525005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525005A5 JP2020525005A5 JP2019570807A JP2019570807A JP2020525005A5 JP 2020525005 A5 JP2020525005 A5 JP 2020525005A5 JP 2019570807 A JP2019570807 A JP 2019570807A JP 2019570807 A JP2019570807 A JP 2019570807A JP 2020525005 A5 JP2020525005 A5 JP 2020525005A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- cancer
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 137
- 102000036639 antigens Human genes 0.000 claims description 135
- 108091007433 antigens Proteins 0.000 claims description 135
- 239000012634 fragment Substances 0.000 claims description 114
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 42
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 36
- 239000005557 antagonist Substances 0.000 claims description 34
- 150000003384 small molecules Chemical class 0.000 claims description 34
- 150000001413 amino acids Chemical group 0.000 claims description 26
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 25
- 239000000556 agonist Substances 0.000 claims description 22
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 21
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 18
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 10
- 108091008874 T cell receptors Proteins 0.000 claims description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 10
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 10
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 8
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 8
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 8
- 239000012636 effector Substances 0.000 claims description 8
- 239000002955 immunomodulating agent Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 6
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 6
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 6
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 claims description 6
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 6
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 4
- ZADWXFSZEAPBJS-JTQLQIEISA-N 1-methyl-L-tryptophan Chemical compound C1=CC=C2N(C)C=C(C[C@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-JTQLQIEISA-N 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 108060006698 EGF receptor Proteins 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 claims description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 4
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 4
- 101710083287 SLAM family member 7 Proteins 0.000 claims description 4
- 241001632234 Senecavirus Species 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 229940022399 cancer vaccine Drugs 0.000 claims description 4
- 238000009566 cancer vaccine Methods 0.000 claims description 4
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 102000057058 human VSIR Human genes 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 244000309459 oncolytic virus Species 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 108020003519 protein disulfide isomerase Proteins 0.000 claims description 4
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 claims description 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- HXNBAOLVPAWYLT-NVNXTCNLSA-N (5z)-5-[[5-bromo-2-[(2-bromophenyl)methoxy]phenyl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound S\1C(=S)NC(=O)C/1=C/C1=CC(Br)=CC=C1OCC1=CC=CC=C1Br HXNBAOLVPAWYLT-NVNXTCNLSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims description 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 229940125565 BMS-986016 Drugs 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 2
- 108700012439 CA9 Proteins 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 2
- 229940116741 CD137 agonist Drugs 0.000 claims description 2
- 102100038077 CD226 antigen Human genes 0.000 claims description 2
- 229940121697 CD27 agonist Drugs 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 229940123205 CD28 agonist Drugs 0.000 claims description 2
- 229940123189 CD40 agonist Drugs 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 229940124957 Cervarix Drugs 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 241000709698 Coxsackievirus A21 Species 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 229940124884 Engerix-B Drugs 0.000 claims description 2
- 102000000820 Enterotoxin Receptors Human genes 0.000 claims description 2
- 108010001687 Enterotoxin Receptors Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 229940124897 Gardasil Drugs 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 2
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 2
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- -1 IL-1a Proteins 0.000 claims description 2
- 108010073816 IgE Receptors Proteins 0.000 claims description 2
- 102000009438 IgE Receptors Human genes 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102100022337 Integrin alpha-V Human genes 0.000 claims description 2
- 108010042918 Integrin alpha5beta1 Proteins 0.000 claims description 2
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims description 2
- 108700020796 Oncogene Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229940121678 PD-L2 antagonist Drugs 0.000 claims description 2
- 108091008606 PDGF receptors Proteins 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 claims description 2
- 102100024601 Protein tyrosine phosphatase type IVA 3 Human genes 0.000 claims description 2
- 101710138647 Protein tyrosine phosphatase type IVA 3 Proteins 0.000 claims description 2
- 208000010362 Protozoan Infections Diseases 0.000 claims description 2
- 229940124942 Recombivax HB Drugs 0.000 claims description 2
- 108700033496 Recombivax HB Proteins 0.000 claims description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 208000033749 Small cell carcinoma of the bladder Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 229940123803 TIM3 antagonist Drugs 0.000 claims description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims description 2
- 101710170091 Transmembrane glycoprotein NMB Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 2
- 101710178278 Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 102000013127 Vimentin Human genes 0.000 claims description 2
- 108010065472 Vimentin Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 claims description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229950002916 avelumab Drugs 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 230000005889 cellular cytotoxicity Effects 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 229950010640 ensituximab Drugs 0.000 claims description 2
- 229950006370 epacadostat Drugs 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 102000006815 folate receptor Human genes 0.000 claims description 2
- 108020005243 folate receptor Proteins 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims description 2
- 229940124736 hepatitis-B vaccine Drugs 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 claims description 2
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 230000009545 invasion Effects 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960002566 papillomavirus vaccine Drugs 0.000 claims description 2
- 229960005547 pelareorep Drugs 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 229940034080 provenge Drugs 0.000 claims description 2
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 claims description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 101150047061 tag-72 gene Proteins 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 229950007217 tremelimumab Drugs 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 201000007710 urinary bladder small cell neuroendocrine carcinoma Diseases 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 210000005048 vimentin Anatomy 0.000 claims description 2
- 238000002619 cancer immunotherapy Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523649P | 2017-06-22 | 2017-06-22 | |
| US62/523,649 | 2017-06-22 | ||
| PCT/US2018/039036 WO2018237287A1 (en) | 2017-06-22 | 2018-06-22 | Anti-vista antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525005A JP2020525005A (ja) | 2020-08-27 |
| JP2020525005A5 true JP2020525005A5 (enExample) | 2021-07-26 |
Family
ID=64737864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570807A Pending JP2020525005A (ja) | 2017-06-22 | 2018-06-22 | 抗ｖｉｓｔａ抗体および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210139589A1 (enExample) |
| EP (1) | EP3642231A4 (enExample) |
| JP (1) | JP2020525005A (enExample) |
| CN (1) | CN110959013A (enExample) |
| CA (1) | CA3067835A1 (enExample) |
| WO (1) | WO2018237287A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| SG11202008593PA (en) | 2018-03-21 | 2020-10-29 | Five Prime Therapeutics Inc | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| AU2019301120A1 (en) | 2018-07-11 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
| US10577424B1 (en) * | 2019-08-15 | 2020-03-03 | Beijing Mabworks Biotech Co., Ltd. | Antibodies binding VISTA and uses thereof |
| EP4076526A4 (en) * | 2019-12-17 | 2024-07-03 | The Board Of Regents Of The University Of Texas System | Novel ddr1 antibodies and uses thereof |
| EP4199947A4 (en) | 2020-08-18 | 2024-10-16 | Onchilles Pharma, Inc. | Modified porcine pancreatic elastase proteins |
| US12551584B1 (en) * | 2020-12-07 | 2026-02-17 | Actinium Pharmaceuticals, Inc. | Lewis Y radioimmunotherapy for the treatment of cancer |
| CN118515760B (zh) * | 2023-07-28 | 2024-11-12 | 北京亦庄国际蛋白药物技术有限公司 | 抗vista的抗体或其抗原结合片段及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005023617A1 (de) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| US7989595B2 (en) * | 2005-06-20 | 2011-08-02 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US8404235B2 (en) * | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| CN102781963B (zh) * | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | 功能修饰性NAv1.7抗体 |
| US20150231215A1 (en) * | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
| US9783601B2 (en) * | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| CN103502274B (zh) * | 2011-03-03 | 2016-01-06 | 埃派斯进有限公司 | 抗-il-6受体抗体及其使用方法 |
| US9441042B2 (en) * | 2011-11-02 | 2016-09-13 | Apexigen, Inc. | Anti-KDR antibodies and methods of use |
| US9255154B2 (en) * | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| CN104619722B (zh) * | 2012-06-22 | 2022-10-04 | 达特茅斯大学理事会 | 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途 |
| US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| CA2884704C (en) * | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| JP2016521711A (ja) * | 2013-06-10 | 2016-07-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｃｍｖ中和抗原結合性タンパク質 |
| US10273301B2 (en) * | 2013-12-24 | 2019-04-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| MX2017007136A (es) * | 2014-12-05 | 2017-12-04 | Immunext Inc | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. |
| KR102693806B1 (ko) * | 2014-12-11 | 2024-08-09 | 피에르 파브르 메디카먼트 | 항-c10orf54 항체들 및 그들의 용도들 |
-
2018
- 2018-06-22 CA CA3067835A patent/CA3067835A1/en active Pending
- 2018-06-22 WO PCT/US2018/039036 patent/WO2018237287A1/en not_active Ceased
- 2018-06-22 US US16/623,601 patent/US20210139589A1/en not_active Abandoned
- 2018-06-22 JP JP2019570807A patent/JP2020525005A/ja active Pending
- 2018-06-22 EP EP18820203.0A patent/EP3642231A4/en not_active Withdrawn
- 2018-06-22 CN CN201880049287.3A patent/CN110959013A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7386083B2 (ja) | Ｃｄ８０バリアント免疫調節タンパク質及びその使用 | |
| AU2017301880C1 (en) | Immunomodulatory polypeptides and related compositions and methods | |
| CN108884164B (zh) | 用于免疫疗法的经修饰细胞 | |
| JP6096196B2 (ja) | 抗αβＴＣＲ抗体 | |
| EP3556772A1 (en) | Anti-cd19 humanized antibody and immune effector cell targeting cd19 | |
| CA3123303A1 (en) | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) | |
| US20150038682A1 (en) | Antibodies or fusion proteins multimerized via homomultimerizing peptide | |
| AU2018360800A1 (en) | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) | |
| TW202438521A (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| CN110520445A (zh) | 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| EP4182357A1 (en) | Fusion proteins comprising a ligand-receptor pair and a biologically functional protein | |
| IL264104B1 (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| WO2020229844A1 (en) | Binding molecules | |
| CN109789164A (zh) | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 | |
| WO2021252780A2 (en) | Bispecific immune cell engagers with binding specificity for hla-g and another antigen | |
| KR20240114745A (ko) | T-세포 조절 다량체 폴리펩티드 및 이의 사용 방법 | |
| WO2023202280A1 (zh) | 抗B7H6的scFv抗体、其编码基因及其应用 | |
| JP2024540083A5 (enExample) | ||
| Fine et al. | Mechanism-driven design of multispecific antibodies for targeted disease treatment | |
| WO2025148750A1 (zh) | 膜表达il-10及其用途 | |
| AU2024269873A1 (en) | Immunotherapeutic proteins | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| US20250161355A1 (en) | Proteins for modulating cell therapy products and methods of use thereof | |
| WO2025238157A1 (en) | Multispecific binding agent suitable for use in cancer immune therapy | |
| CN117586411A (zh) | 一种结合tnfr2和ccr8的双特异性抗体 |